
The British Business Bank has disclosed that it has deployed more than one billion pounds in financial backing to support the United Kingdom’s life sciences sector. The state lender stated that it has had to adopt an aggressive approach to financing in order to attract further investment from pension funds and assist domestic firms in scaling their operations within the country. This strategic move is designed to address the persistent dearth of capital available to specialist biotechnology and medical technology companies in the UK.
The bank’s total financial commitment to the sector has reached 1.1 billion pounds. This sum includes 832 million pounds distributed across 20 dedicated life science funds, alongside 302 million pounds invested directly into numerous domestic scale-ups. The direct investment is intended to increase the size of funding rounds for established companies. Recent high-profile investments include a 25 million pound allocation to Alchemab Therapeutics, which represents the bank’s largest single financial support to a life science firm to date. Additionally, the state lender provided 15 million pounds to T-Therapeutics, a spinout from Cambridge University.
Leandros Kalisperas, the bank’s chief investment officer, explained that the institution must throw the kitchen sink at the problem of financing life sciences. He noted that the bank is actively working to encourage more investment from pension funds by communicating the possibilities for these institutional investors to get involved. The bank has been attempting to entice signatories of the Mansion House accord to unlock further pension capital for private assets and venture capital firms. Under this accord, 11 of the UK’s top pension money managers committed to investing five per cent of their assets in private markets and unlisted equities by 2030.
However, a recent update indicated that the vast majority of committed capital for UK private markets has been allocated to property, accounting for 70 per cent of the total 11.1 billion pounds. In contrast, only 500 million pounds was invested into private equity. The sector has long faced challenges from acquisitions and relocations driven by overseas buyers who offer better funding and scaling conditions. For instance, US pharmaceutical giant Merck & Co acquired ophthalmology biotech firm Eyebio in a deal worth up to 3 billion dollars in 2024, while Japanese medical technology company Terumo acquired Oxford University spinout Orgonox for 1.5 billion dollars last year.
Chris Molloy, chief executive of the Bio Industry Association, stated that the increase in funding from the bank would enable the most promising businesses to scale and remain in the UK. The lender also confirmed it committed 58 million euros to Sofinnova Crossover Fund II, a Paris-based fund that backs firms across Europe. Kalisperas argued that the state cannot rely solely on UK-only funds to attract deep pools of capital for specialist firms, emphasising the need to encourage European specialists to invest in UK companies.
Looking ahead, Kalisperas expects investors to shift more capital into the sector as the artificial intelligence cycle matures. He noted that drug discovery can change through AI, suggesting that life sciences are linked to broader technological trends. This funding commitment follows the National Wealth Fund investing in One North Quay in Canary Wharf. The fund committed 147 million pounds of debt financing towards the development, which is expected to become one of the largest commercial science buildings in Europe. The project is set to be completed in 2028, with total financing reaching 368.5 million pounds including contributions from Barclays and Emirates NBD.
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.